Get the Stockscreener App
3.56
8.87%
0.29
After Hours:
2.75
-0.81
-22.75%
Neuronetics Inc stock is traded at $3.56, with a volume of 783.00K.
It is up +8.87% in the last 24 hours and up +126.75% over the past month.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
See More
Previous Close:
$3.27
Open:
$3.27
24h Volume:
783.00K
Relative Volume:
1.01
Market Cap:
$198.12M
Revenue:
$69.23M
Net Income/Loss:
$-33.10M
P/E Ratio:
-3.0169
EPS:
-1.18
Net Cash Flow:
$-39.26M
1W Performance:
+4.40%
1M Performance:
+126.75%
6M Performance:
+97.78%
1Y Performance:
+1.14%
1-Day Range:
$3.2201
$3.65
1-Week Range:
$2.88
$3.65
52-Week Range:
$0.52
$5.0699
Neuronetics Inc Stock (STIM) Company Profile
Name
Neuronetics Inc
Sector
Industry
Phone
877-600-7555
Address
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
3.56 | 198.12M | 69.23M | -33.10M | -39.26M | -1.18 |
|
TMO
Thermo Fisher Scientific Inc
|
572.71 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
210.01 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.64 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
209.96 | 38.11B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
460.56 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-13-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-13-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Feb-06-20 | Initiated | BTIG Research | Buy |
| Jul-24-18 | Initiated | Canaccord Genuity | Buy |
View All
Neuronetics Inc Stock (STIM) Latest News
Neuronetics announces public stock offering By Investing.com - Investing.com South Africa
Neuronetics announces public stock offering - Investing.com India
Neuronetics Announces Launch of Underwritten Public Offering of Common Stock - The Manila Times
Major Stock Offering Alert: Neuronetics Takes Bold Step to Raise Capital Through Public Markets - StockTitan
Are Smart Investors Making the Right Decision? Neuronetics Inc (STIM) - SETE News
Medical Transcranial Magnetic Stimulator Market Generated - openPR
Neuronetics Inc (STIM)’s stock chart: A technical perspective - US Post News
Market Momentum Report: Neuronetics Inc (STIM)’s Positive Close at 3.45 - The Dwinnex
Neuronetics Inc (STIM) rating downgrades by William Blair - Knox Daily
Unlocking the Healthcare Boom: Why Neuronetics is a Game-Changer for Investors - Jomfruland.net
Why Neuronetics Inc (STIM) Is Skyrocketing So Far In 2025 - Insider Monkey
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Drops By 35.8% - MarketBeat
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression - The Manila Times
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression -January 29, 2025 at 08:32 am EST - Marketscreener.com
NeuroStar Unveils Two Significant Publications on TMS Therapy for Depression -January 29, 2025 at 08:31 am EST - Marketscreener.com
Neuronetics, Inc. Unveils Two Significant Publications on TMS Therapy for Depression - Marketscreener.com
Neuronetics (NASDAQ:STIM) shareholders are up 34% this past week, but still in the red over the last five years - Yahoo Finance
Breakthrough Depression Treatment Achieves Universal Success Rate, Research Confirms - StockTitan
Neuronetics Reports 2024 Revenue Growth, Reveals Optimistic 2025 Guidance - MSN
Neuronetics (NASDAQ: STIM) Files 8-K with Preliminary Financial Information - Defense World
Neuronetics, Inc. Announces Unaudited Revenue Results for Fourth Quarter and Full Year 2024 - Marketscreener.com
Neuronetics, Inc. (NASDAQ:STIM) Sees Significant Drop in Short Interest - MarketBeat
Neuronetics forecasts revenue growth and cost savings post-acquisition - Investing.com India
Neuronetics Projects Growth Following Greenbrook Acquisition - TipRanks
Neuronetics Provides Business Update and Issues 2025 Guidance - The Manila Times
Neuronetics Projects Strong 2025 Growth, Expands NeuroStar Depression Treatment to Teens - StockTitan
Neuronetics, Inc.'s (NASDAQ:STIM) Shares Leap 43% Yet They're Still Not Telling The Full Story - Simply Wall St
Transcranial Magnetic Stimulator Market Growth in Future Scope - openPR
Transcranial Magnetic Stimulator Market Report, Size, Trends, - openPR
Critical Survey: Neuronetics (NASDAQ:STIM) vs. Tenon Medical (NASDAQ:TNON) - Defense World
Neuronetics Awards Stock Units to New Employee Bill Leonard - MSN
Neuronetics (NASDAQ:STIM) Is Making Moderate Use Of Debt - Simply Wall St
HighTower Advisors LLC Increases Stock Holdings in Neuronetics, Inc. (NASDAQ:STIM) - Defense World
Neuronetics (STU:NRC) Future 3-5Y EPS without NRI Growth Ra - GuruFocus.com
Neuronetics Revamps TrakStar System, Streamlining Patient Data Management - MSN
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Neuronetics Grants Strategic 50,000 PRSU Inducement Award to Key New Employee - StockTitan
Neuronetics' SWOT analysis: merger impact on neurohealth stock By Investing.com - Investing.com Australia
Neuronetics Unveils Strategic Performance-Based Stock Awards Targeting Cash Flow Breakeven by 2025 - StockTitan
Neuronetics' SWOT analysis: merger impact on neurohealth stock - Investing.com
Neuronetics, Greenbrook TMS close transaction - Medical Buyer
Neuronetics Expands with Greenbrook TMS Acquisition - TipRanks
Madryn Provides Update on Holdings of Greenbrook TMS Inc. - The Manila Times
Neuronetics and Greenbrook TMS Announce Closing of Transaction - The Manila Times
Reviewing Stryker (NYSE:SYK) & Neuronetics (NASDAQ:STIM) - Defense World
Neuronetics' SWOT analysis: merger, market challenges shape TMS stock outlook - Investing.com Nigeria
Neuronetics (STU:NRC) 3-Year EPS without NRI Growth Rate : 9.40% (As of Sep. 2024) - GuruFocus.com
Neuronetics Inc Stock (STIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):